Sun Pharma to sell manufacturing unit in Ireland
Sun Pharma is planning to sell its manufacturing facility in Ireland which it has acquired from Ranbaxy earlier. Sun Pharma had completed the USD 4 billion acquisition of Ranbaxy in March, almost a year after announcing the deal.Citing reasons for rationalizing the company’s manufacturing operations; the Managing Director Dilip Sanghvi has earlier said that disinvestment will...
Login or Register to read the full article
Sun Pharma is planning to sell its manufacturing facility in Ireland which it has acquired from Ranbaxy earlier. Sun Pharma had completed the USD 4 billion acquisition of Ranbaxy in March, almost a year after announcing the deal.
Citing reasons for rationalizing the company’s manufacturing operations; the Managing Director Dilip Sanghvi has earlier said that disinvestment will be initiated.
"...decisions are being made to either close or divest some of our manufacturing facilities. Currently, the Ireland facility has been identified for divestment," Sun Pharma spokesperson said in an e-mailed response.
The spokesperson did not comment on details such as the prospective buyer or valuation of the plant.
"In March this year, Sun Pharma successfully completed the merger of Ranbaxy. This has provided an opportunity to optimise overall manufacturing network in terms of capacity, costs and efficiencies," the spokesperson added.
Citing reasons for rationalizing the company’s manufacturing operations; the Managing Director Dilip Sanghvi has earlier said that disinvestment will be initiated.
"...decisions are being made to either close or divest some of our manufacturing facilities. Currently, the Ireland facility has been identified for divestment," Sun Pharma spokesperson said in an e-mailed response.
The spokesperson did not comment on details such as the prospective buyer or valuation of the plant.
"In March this year, Sun Pharma successfully completed the merger of Ranbaxy. This has provided an opportunity to optimise overall manufacturing network in terms of capacity, costs and efficiencies," the spokesperson added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd